| Literature DB >> 36105465 |
Hossein Biganeh1,2, Mahdi Kabiri3, Yahya Zeynalpourfattahi4, Rose Meire Costa Brancalhão5, Mehrdad Karimi4, Mohammad Reza Shams Ardekani6, Roja Rahimi2,3.
Abstract
Silk cocoon, naturally produced by silkworms scientifically named Bombyx mori L. (Lepidoptera, Bombycidae), is one of the well-known medicinal agents with several therapeutic activities. The present study aims to review the various aspects of the silk cocoon, including chemical composition, traditional uses, biological and biotechnological activities, and toxicological issues, to provide a scientific source for scholars. For this purpose, Electronic databases including PubMed, Scopus, Google Scholar, Web of Science, and traditional literature, were searched up to December 2021. According to the historical data, silk farming is acknowledged as one of the most ancient agricultural findings. The silk is generally composed of 75-83% fibroin, 17-25% sericin, and 1-5% non-sericin components, including secondary metabolites, wax, pigments, carbohydrates, and other impurities. Flavonoids, especially quercetin and kaempferol, alkaloids, coumarin derivatives, and phenolic acids, are among the secondary metabolites isolated from the silk cocoon. In recent years the biological properties of the silk cocoon, especially its major proteins, namely fibroin and sericin, have drawn special attention. Scientific literature has investigated several pharmacological effects of the silk cocoon and its ingredients, including cardioprotective, antioxidant, anticancer, antidiabetic, antihyperlipidemia, gastroprotective, as well as ameliorated skin health activities. In addition, it has been extensively taken into consideration in drug delivery and tissue engineering study fields. Furthermore, its toxicity is in acceptable range.Entities:
Keywords: Aminoacid; Fibroin; Heart; Protein; Sericin; Silk cocoon
Year: 2022 PMID: 36105465 PMCID: PMC9465338 DOI: 10.1016/j.heliyon.2022.e10496
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Major chemical constituents of silkworm cocoons. a: silkworm lifecycle. b: major amino acids found in silk fibroin and c: silk sericin, d: secondary metabolites found in silk cocoons.
Pharmacological activities of silk cocoon.
| Pharmacological activity | Intervention | Dose | Duration (weeks) | Model | Results | Reference |
|---|---|---|---|---|---|---|
| Cardiovascular activity | Different traditional formulations from cocoon silk extract | - | ∼4 (30 days) | Isoproterenol-induced cardiotoxicity in rats | Suppression of heart damage through ↓cardiac marker enzymes (CK-MB and troponin), heart weight to body weight ratio, degree of myonecrosis and filtration of inflammatory cells, and lipid peroxidation; Improvement of heart recovery and cardiac antioxidant capacity | [ |
| Pretreatment by ethanolic extracts of silk cocoon | 250 and 500 mg/kg/d | 4 | Isoprenaline-induced myocardial infarction in rats | ↓inflammation, redness, capillary dilation, and scar formation in histopathologic findings; Improvement of various cardiac enzymes and heart weight/body weight ratio | [ | |
| Pretreatment with traditional formulation (Khamira Abresham Hakim Arshad Wala) | 200 mg/kg/d | 1 | Doxorubicin-induced cardiotoxicity in rats | ↓cardiac-related enzymatic changes and tissue damages; ↑antioxidant activities (reinstatement of MDA and GSH levels) | [ | |
| Anti-hyperlipidemic activity | Silk protein with different fibroin/sericin compositions: F100 (pure fibroin), F81 (81:19 fibroin/sericin, w/w) or F50 (50:50 fibroin/sericin, w/w) | - | 6 | High fat-fed mice | ↓body weight and enhanced lipid profile; ↓body fat, TG and total plasma chol levels, atherogenic index and free fatty acid level; ↑HDL-C level; ↑fecal lipid excretion, inhibition of lipogenesis, and regulation of adipokine production; These effects were increased by increasing the amount of sericin in the diet | [ |
| Silk cocoon extract | 500 mg/kg/d | 6 | Cholesterol diet-induced hyperlipidemia and atherosclerosis in rabbits | ↓atherosclerotic plaques size; ↑body weight and HDL-C levels | [ | |
| Sericin-derived oligopeptides | 50–1000 μg/ml | - | Caco-2 cell line | ↓chol uptake in the cell line | [ | |
| Sericin-derived oligopeptides with high fat diet | 10, 50, and 200 mg/kg/d | 4 | High cholesterol-fed rats | ↓total serum and non-HDL chol | ||
| Silk sericin with high fat diet | 25 and 50 μg/ml | - | Caco-2 cell line | ↓30% of chol uptake in the cell line | [ | |
| 10, 100, and 1000 mg/kg/d | 2 | High cholesterol-fed rats | ↓total serum and non-HDL chol | |||
| Sericin with high fat diet | 4% w/w | 5 | High fat-fed rats | ↓serum levels of TG, chol, phospholipids, and free fatty acids; ↓VLDL-TG, VLDL-C, LDL-C, and LDL-phospolipids; ↓liver TG and lipogenic enzymes like glucose-6-phosphate dehydrogenase and malic enzyme; ↑serum adiponectin; final body and white adipose tissue weight remained unchanged | [ | |
| Sericin with high fat diet | 1,000 mg/kg/d | 4 | High-fat diet-induced obese mice | Not entirely recovery of biochemical and biometric changes induced following obesity induction; No impact on mice bowel transit time; ↑lipid excretion; restored intestinal wall morphometry; | [ | |
| Antioxidant and Antitumor activities | Pretreatment with sericin protein | 0.375, 0.75, and 1.5 g/kg/d | ∼4 (30 days) | Alcohol-induced hepatic injury in mice | ↓alcohol concentration in serum; ↑urine level of alcohol; Restoration of elevated antioxidant enzymes like MDA, GSH, and SOD to normal values; Restoration of hepatic mitochondria to normal form; Normal histology with mild congestion of central vein at the dose of 1.50 g/kg | [ |
| Silk sericin | - | - | Enzymatic assay | Vigorous scavenging activity against hydroxyl, superoxide, and DPPH radicals; Potent antioxidant action on the peroxidation of linoleic acid; Significant reducing power and ferrous-ion-chelating activity | [ | |
| Silk sericin hydrolysates obtained by different proteases | - | - | Enzymatic assay | Significant reducing power and ferrous-ion-chelating activity of all of the silk sericin hydrolysates; Pronounced radical scavenging and lipid peroxidation activity of alcalase hydrolysates than other proteases | [ | |
| Silk sericin | 35, 50, 100, and 150 ng/ml | - | Hydrogen peroxide-induced oxidative stress in the skin fibroblast cell line (AH927) | ↓MDA, LDH, and catalase cellular release in the pre-incubated cells with sericin before H2O2 treatment; ↑viable cells at 35 ng/ml compared to H2O2-treated cells | [ | |
| Silk sericin with 1,2-diethylhydrazine for the initial 10 weeks | 30 g/kg/d | ∼21 (115 days) | 1,2-dimethylhydrazine-challenged mice | ↓incidence of colon carcinoma; ↓number of colon adenomas; ↓BrdU labeling index of colonic proliferating cells; ↓expression of colonic c-myc and c-fos proteins; ↓levels of colonic 8-hydroxydeoxyguanosine, 4-HNE, and inducible nitric oxide synthase protein | [ | |
| Silk sericin | 25-1,600 mg/ml | - | Human colorectal cancer SW480 cell line | ↓cell viability; triggering cell apoptosis through ↑caspase-3 and ↓Bcl-2 expression; Induction of cell cycle arrest at the S phase | [ | |
| Treatment with silk sericin | 3%/d | 4 | 1,2-dimethylhydrazine-treated rats | ↓colon mucosal lipid peroxide; ↓number of aberrant crypt foci in all areas of the colon; ↑antioxidant activity | [ | |
| Topical sericin immediately after UVB treatment | 5 mg/d | 1 | UVB-induced skin lesion in hairless mice | ↓formation of skin lesion (↓area and intensity of red color of the lesions); ↓epidermal thickness; ↓PCNA; ↓4-HNE and COX-2 protein expression | [ | |
| Topical sericin immediately after 7,12-dimethylbenz anthracene (DMBA) treatment followed 1 week later by UVB irradiation twice weekly for 22 weeks | 5 mg/d | 22 | UVB-induced tumor promotion in the DMBA-initiated mouse skin | ↓tumor incidence and multiplicity | ||
| Gastrointestinal protective activity | Co-administration of beef tallow and sericin | 40 g/kg/d | 3 | High fat-fed rats | ↑fecal IgA and mucin (indices of intestinal immune and barrier functions, respectively); ↓acetate and n-butyrate cecal organic acids; No change in microflora profile in cecal digesta and fecal secondary bile acids between high fat-diet with or without sericin | [ |
| Pretreatment with sericin protein | 0.2, 0.4, | ∼4 (30 days) | Alcohol-induced gastric injury in mice | ↓alcohol concentration in serum; ↑alcohol concentration in urine; Reversion of gastric damage indicators including MDA, GSH, GSH-PX, and SOD; Gastric mucosal mitochondria restoration | [ | |
| Pretreatment with sericin protein | 40 g/kg/d | 1 | Atropine-induced constipation in rats | Notable decreased in the fecal wet and dry weight in the control group; No change in fecal wet or dry weight in sericin fed rats; Higher water content in sericin group than the control group (regardless of atropine administration) | [ | |
| Co-administration of sericin, white egg albumin and different microelements | 30 g/kg/d | ∼2 (12 days) | Male Sprague-Dawley rats | ↑apparent absorption of Zn, Fe, Mg and Ca; no change in their urinary excretion; ↑their bioavailability; No change in final body weight, food intake amount and fecal dry weight | [ | |
| Hypoglycemia and its related complications activities | SF peptides | 50 mg/ml | - | Insulin resistant HepG2 cells | ↑glucose and lipid metabolism; ↑glucose consumption; ↓TG levels; ↓ROS, MDA, TNF-α and IL-6; ↑SOD and catalase activity; ↑total antioxidant capacity; ↑glucose consumption and glycogen accumulation, whereas ↓TG levels, ROS, and MDA in SF and metformin (0.01 mg/ml) combination treatment compared to metformin or SF alone | [ |
| Acid-hydrolyzed silk peptides | 0.05, 0.1 and 0.5 g/kg/d | 8 | Non-obese insulin-insufficient partial pancreatectomized (Px) rat model of T2DM | ↑food efficiency and body weight gain; partially protection against Px-induced bone mineral density and lean body mass decrement; ↑oral glucose and maltose and insulin tolerance; ↑insulin secretory capacity | [ | |
| Acid-hydrolyzed silk peptides with high-fat diet | 50 and 200 mg/kg/d | 6 | High-fat diet-induced obesity | Inhibition of body mass gain and the expression of adipogenic transcription factors in subcutaneous (SAT) and visceral adipose tissue (VAT); ↓blood glucose and adipocyte size increment; ↑oral glucose tolerance; ↓HbA1c; ↑GLUT4 and UCP3 expression; ↓ubiquitin proteasome and promoted myoblast determination protein 1 (MyoD)/myogenic factor 4 (myogenin) expression | [ | |
| Acid-hydrolyzed silk peptides | 25, 50, 100, 200, and 400 μM | - | 3T3-L1 adipocytes | ↓lipid accumulation; ↓expression of the adipogenic markers (C/EBPα and PPARγ) | ||
| Ethanolic extract from the green cocoon sericin layer | 150, 250, and 350 mg/kg/d | 7 | T2DM mice | Improved oral glucose tolerance and insulin tolerance; ↓blood glucose level; ↑insulin and HbA1C levels; ↑islet area and the number of insulin-positive beta cells; ↓HOMA-IR and ↑ISI; ↓NFκB, IL-6, and TNF-α; ↑SOD and GSH-Px activities; | [ | |
| A peptide fraction of sericin hydrolysate | 0–400 μg/ml | - | α-glucosidase inhibition enzymatic assay | Similar α-glucosidase inhibitory activity as acarbose | [ | |
| Silk sericin hydrolysate | 0.8%/d (g%) | 4 | T2DM mice | ↓fasting blood glucose, fasting plasma insulin, and glycosylated serum protein levels; Improved oral glucose tolerance and insulin tolerance; Ameliorated damaged β-cells and the liver tissue; ↑expression of insulin receptor, insulin receptor substrate, PI3K, phosphorylated-AKT, hepatic kinase, GLUT4, glycogen synthase, GSK3β, GLK, PFK1, PKM2, and AMPKα (associated with insulin metabolism and glycolysis); ↓expression of G6Pase, PCK, and ACC, (associated with gluconeogenesis and lipid metabolism in the liver); ↓expression of TNF-α, | [ | |
| Hydrolyzed SF | 20% drinking water and a mixture of hydrolyzed SF | 6 | Pancreatic | ↑pancreatic β-cell numbers; ↑blood insulin level; ↓blood glucose concentration; No change in body weight; ↑the number of PCNA and the ratio of BrdU positive cells; ↓number of apoptotic cells; ↑the expression of transcription factors involved in β-Cells regeneration; ↑the number of insulin-positive cells | [ | |
| Silk sericin | 2.4 g/kg/d | 5 | T2DM rats | ↓blood glucose concentration; ↓the expression levels of MKK6, p-p38MAPK, NF-κB, IL-1β, IL-6, NLRP3 and caspase-1; ↓pathological changes-related to diabetes induction; No change in p38MAPK expression | [ | |
| Silk sericin | 2.4 g/kg/d | 5 | T2DM rats | ↓serum growth hormone levels; ↓growth hormone expression; ↑serum testosterone and IGF-1 levels; upregulation of testicular growth hormone receptor and IGF-1 expression; improved spermatogenic activity by regulating the growth hormone/IGF-1 axis | [ | |
| Silk sericin instillation into the eyes of the rats five times a day following corneal abrasion | 10% | 3 days | Corneal wound-induced Otsuka Long-Evans Tokushima Fatty rats (T2DM model) | ↑wound healing progression and wound size reduction; Complete wound healing 48 h after abrasion | [ | |
| Silk sericin | 2.4 g/kg/d | 5 | Sciatic-related nerve cells injuries in T2DM rats | ↓serum blood glucose level; promotion of neurofilament protein expression in the sciatic nerve and nerve growth factor in L4–6 spinal ganglion and anterior horn cells; ↓the expression of neuropeptide Y in spinal ganglion and anterior horn cells | [ | |
| Silk sericin | 2.4 g/kg/d | 5 | T2DM rats | ↓serum blood glucose concentration; ↓serum growth hormone level; ↓hippocampus growth hormone expression; ↑serum IGF-1 level; ↑IGF-1 and growth hormone receptor in the hippocampus; improved disorders of the growth hormone/IGF-1 axis | [ | |
| Neuropsychological activity | A syrup made from silk cocoon aqueous extract | 5 ml of syrup containing 250 mg dried extract twice daily | 12 | Patients with mixed anxiety-depressive disorder | ↓mean of anxiety and depression scores in week 6 and week 12 compared to control group | [ |
| Silk fibroin nanoparticles | A single dose injection in center of lesion area of the sensori-motor cortex | 4 days | Traumatic Brain Injury Model | ↓brain damage and recovery of long-term neurological functions; higher viability of primary cell cultures of neurons and astrocytes on silk fibroin matrices under oxygen-glucose deprivation compared to 2D conditions on plastic plates | [ | |
| silk fibroin protein enzymatic hydrolysate (FPEH) | 0, 280, 400 and 600 mg of FPEH per day in two divided doses | 3 | Healthy adults with an average age of 55 | dose-dependent increases in memory quotient score (MQ), the learning gradient, the numbers of words remembered, the retrieval efficiency, and drawing/recall; The optimal dose for FPEH was 400 or 600 mg, depending on the end point measured; No adverse effects were reported | [ | |
| silk amino acid preparation (SAA) | 50, 160, or 500 mg/kg | 30 days | Parkinson's disease (PD) model rats | Improvement of 6-OHDA-induced impaired pole test performances; improvement of increased using rate of ipsilateral forelimb in cyclinder test and apomorphine-induced circling behavior of PD rats; attenuation of 6-OHDA-induced loss of neurons as well as decreases in dopamine and its metabolites | [ | |
| Skin health and wound healing activities | Pure silk (100% natural silk) dressing | - | 48 | Patients with burn wounds covering more than 10% of their total body surface area | ↓need for further surgery and scarring compared to patients treated with nylon mesh and collagen; High satisfaction with respect to the aesthetic outcomes; Fast re-epithelization; ↓unpleasant dressing changes frequencies | [ |
| Sodium alginate functionalized with silk sericin/AgNPs hydrogel dressing | Sericin (0.5% w/v); AgNO3 (0.2 mmol/l); Sodium alginate (2% w/v); dressing replacement every 2 days | 2 | Artificial wound-created in rats | Complete wound healing on day 12; ↓bacterial colony numbers; ↑wound contraction ratio; No pus and no inflammation occurrence | [ | |
| AgNPs-sericin/poly (vinyl alcohol) dressing | Sericin (2% w/v); AgNO3 (0.2 mM/l) dressing replacement every 2 days | 2 | Artificial wound-created in rats | ↑wound healing speed; accelerated wound area closure; ↑antibacterial activity | [ | |
| SF-based hydrogels | 3%/d | 8 | Rabbit model of hypertrophic scarring | Lighter wound color and closely similar to the surrounding normal skin color in SF hydrogel-treated group; Softened scar texture; ↓scar hyperplasia index | [ | |
| silkworm cocoon sol-gel film | - | 2 | Artificial wound-created in rabbits | ↑wounds healing rate; rapid ↓ of the wound size and inflammation; successful reconstruction of intact and thickened epidermis | [ |
AMPKα: AMP-activated protein kinase-α; BrdU: Bromodeoxyuridine; COX-2: Cyclooxygenase 2; Chol: C: Cholesterol; CK-MB: Creatine kinase-MB; DPPH: 2,2-diphenyl-1-picrylhydrazyl; GLK: Germinal center kinase-like kinase; GLUT4: Glucose transporter type 4; G6Pase: Glucose 6-phosphatase; GSH: Glutathione; GSH-PX: Plasma glutathione peroxidase; GSK3β: Glycogen synthase kinase 3 β; HDL: High-density lipoprotein; 4-HNE: 4-hydroxynonenal; HOMA-IR: Homeostatic model assessment; IGF-1: Insulin-like growth factor 1; IL-6: Interleukin 6; ISI: Insulin sensitivity index; LDH: Lactate dehydrogenase; MDA: Malondialdehyde; NF-κB: Nuclear factor kappa light chain enhancer of activated B cells; NP: Nanoparticle; Px: Pancreatectomized; PCK: Phosphoenolpyruvate carboxykinase; PCNA: Proliferating cell nuclear antigen; PFK-1: Phosphofructokinase-1; PI3K: Phosphatidylinositol 3-kinase; PKM-2: Tumor M2-pyruvate kinase; P38MAPK: P38 mitogen-activated protein kinases; PPARγ: Peroxisome proliferator-activated receptor γ; ROS: Reactive oxygen species; SAT: Subcutaneous adipose tissue; SF: Silk fibroin; SOD: Superoxide dismutase; T2DM: Type 2 diabetes mellitus; TG: Triglyceride; TNF-α: Tumor necrosis factor-α; UCP3: Mitochondrial uncoupling protein 3; VAT: Visceral adipose tissue; VLDL: Very-low-density lipoprotein.